Back to top

Analyst Blog

Zacks Equity Research

Watson's Generic Product Approved

IRWD VRX

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Watson Pharmaceuticals, Inc. recently announced that it gained US Food and Drug Administration (FDA) approval for its generic version of Ferring Pharmaceuticals' Lysteda (tranexamic acid) tablet. The company intends to launch the product soon.

Lysteda tablet is approved for the treatment of cyclic heavy menstrual bleeding. According to IMS Health, Lysteda generated US revenues of approximately $25 million for the 12 months ending November 30, 2012.

Ferring has filed patent infringement lawsuits against Watson Pharma regarding Lysteda - these litigations are still pending.

FDA approval for Lysteda comes a few days after Watson Pharma announced that it is seeking FDA approval for its generic version of Millennium Pharma’s Velcade (bortezomib). Millennium Pharma is a wholly-owned subsidiary of Takeda Pharma (TKPYY). The abbreviated new drug application (ANDA) was filed by Actavis, Inc. Actavis was acquired by Watson Pharma in October 2012.

Our Recommendation

We currently have a Neutral recommendation on Watson Pharma, which carries a Zacks #3 Rank (Hold). We are positive on the Actavis acquisition, which will be immediately accretive to earnings. With the Actavis acquisition, Watson Pharma has become the third largest generic pharmaceutical company in the world. The company expects to generate annual cost (SG&A, R&D, corporate, purchasing and raw material supply) synergy savings of $300 million within three years.

Watson Pharma also announced its intention to adopt a new global name Actavis from 2013. The company will start trading under a new symbol on the New York Stock Exchange in 2013.

Currently, pharma companies like Valeant Pharmaceuticals International (VRX - Snapshot Report) and Ironwood Pharmaceuticals (IRWD - Analyst Report) carry a Zacks #1 Rank (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%